Delivery Order SPE2DB24D2101-SPE2DB25FKMGV
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,829.29 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. This firm fixed-price delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $16,071.75 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $12,726.40 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, with an ultimate completion date of July 28, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $14,539.96 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 8, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- The Defense Logistics Agency awarded a delivery order valued at $12,735.09 to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Prolia 60 mg/ml syringes. This is a firm fixed price, non-set-aside contract with a completion date of September 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a competitive award under the company's existing pharmaceutical supply framework with the federal government. This...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $10,714.50 to AmerisourceBergen Drug Corp for PROLIA 60 mg/ml syringes, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical prime vendor agreement with DLA Troop Support. The product will be delivered to the contractor's location in...
- The Defense Logistics Agency awarded a $26,999.75 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Prolia 60 mg/ml syringes. This firm fixed price contract is non-competitive with no set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Prolia 60 mg/mL syringes, valued at $11,629.70. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, and represents a non-set-aside competitive award. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child order under a larger...
- The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $14,887.74 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Prolia 60 mg/ml syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 20, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $15,697.68 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 4, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken. This delivery order is issued under...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKMGVDelivery Order
The Defense Logistics Agency awarded a $26,034.19 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes under a firm fixed-price contract. The delivery order, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a competitively awarded non-set-aside procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to military and veteran healthcare systems. The Prolia delivery supports the Defense Health Agency and other federal healthcare customers' pharmaceutical procurement needs through DLA's medical supply chain, continuing the company's established role as a primary vendor for specialized pharmaceutical products across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.0k | 7/14/25 |